Immune Shielding of Human Heart Valves: A Proof-of-Concept Study of HLA-Targeting Therapy for Transplantations

Marijn C. Peters, Arnaud Zaldumbide, Esmee J. Groeneveld, Martijn J.W.E. Rabelink, Janneke H. Peerlings, Antoon van den Bogaerdt, Carlijn V.C. Bouten, Rob C. Hoeben, Marie Jose Goumans*, Abraham van Wijk*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Children born with defective heart valves require multiple donor valve replacements throughout life, because these cannot grow and can cause early failure through immune degeneration. This study tests the lentiviral delivery of viral immune evasion genes US2 and human serpin 9 to shield human heart valves from immune rejection. The results show we can efficiently down-regulate human leukocyte antigen expression in heart valve cells and in intact heart valve tissue resulting in decreased activity of a human leukocyte antigen–reactive CD8+ T-cell clone without inducing cytotoxicity. This study demonstrates immune shielding of human heart valves and brings us closer to a durable valve graft in pediatric patients.

Original languageEnglish
Pages (from-to)1345-1359
Number of pages15
JournalJACC: Basic to Translational Science
Volume9
Issue number11
Early online date11 Sept 2024
DOIs
Publication statusPublished - Nov 2024

Keywords

  • congenital heart disease
  • heart valves
  • immune evasion
  • tissue bioengineering

Fingerprint

Dive into the research topics of 'Immune Shielding of Human Heart Valves: A Proof-of-Concept Study of HLA-Targeting Therapy for Transplantations'. Together they form a unique fingerprint.

Cite this